Cargando…
Anti-scarring effects of conbercept on human Tenon’s fibroblasts: comparisons with bevacizumab
BACKGROUND: Safely inhibiting the formation of scar in the glaucoma filtration surgery (GFS) has always been an issue for clinical glaucoma doctors. Anti-vascular endothelial growth factor (VEGF) agents can reduce angiogenesis, and anti-placental growth factor (PIGF) agents can affect reactive glios...
Autores principales: | Zuo, Lei, Zhu, Shaopin, Gu, Shengjie, Xu, Xun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131424/ https://www.ncbi.nlm.nih.gov/pubmed/37101202 http://dx.doi.org/10.1186/s12886-023-02914-4 |
Ejemplares similares
-
In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery
por: Zhang, Yuanyuan, et al.
Publicado: (2019) -
SPARC is expressed in scars of the Tenon’s capsule and mediates scarring properties of human Tenon’s fibroblasts in vitro
por: Fuchshofer, Rudolf, et al.
Publicado: (2011) -
Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium
por: Park, Young Min, et al.
Publicado: (2015) -
Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Shen, Yinchen, et al.
Publicado: (2022) -
In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon’s fibroblasts: comparisons with mitomycin C
por: Seet, Li-Fong, et al.
Publicado: (2012)